Visceral Leishmaniasis (Kala-azar) Therapeutics Market Size, Product Pipelines, Clinical Trials, Latest Developments, Demand and Growth Forecast 

What is the Visceral Leishmaniasis (Kala-azar) Therapeutics Market and what are its most recent trends 

The Visceral Leishmaniasis (Kala-azar) Therapeutics Market is undergoing rapid transformation, driven by the rising burden of the disease, growing research activity, and expanded access to care in endemic regions. Visceral leishmaniasis, also known as Kala-azar, is a life-threatening disease caused by Leishmania parasites transmitted through the bite of infected sandflies. It primarily affects internal organs, such as the spleen, liver, and bone marrow. Over 90 percent of cases are concentrated in countries including India, Brazil, Sudan, South Sudan, and Ethiopia, creating strong regional demand for effective therapies. 

Recent trends in the Visceral Leishmaniasis (Kala-azar) Therapeutics Market highlight a shift from conventional therapies to advanced treatment regimens. For instance, liposomal amphotericin B has become a first-line treatment in many national programs due to its reduced toxicity and improved cure rates. Combination therapies, such as paromomycin with miltefosine, are being adopted for their superior efficacy and to reduce the risk of drug resistance. Furthermore, the market is witnessing technological innovation, with companies focusing on heat-stable formulations and single-dose treatment options suitable for low-resource settings. The push for shorter, more tolerable treatment courses is reshaping product development strategies across the market. 

 

What is driving the Visceral Leishmaniasis (Kala-azar) Therapeutics Market demand 

The demand in the Visceral Leishmaniasis (Kala-azar) Therapeutics Market is significantly influenced by the increasing incidence of the disease in endemic regions. For example, in India’s Bihar state alone, over 30,000 cases were reported between 2018 and 2023, underscoring the need for scalable and effective treatment options. Across East Africa, regions such as Sudan and Somalia have seen spikes in transmission, driving therapeutic requirements upward. Datavagyanik notes that the disease’s re-emergence in conflict-affected areas further complicates control efforts and amplifies the demand for field-ready therapies. 

Health system improvements and active case detection campaigns are contributing to increased treatment rates. Mobile medical units, public health initiatives, and improved diagnostic coverage have helped reduce underreporting. For instance, Nepal and Bangladesh have increased their treatment outreach by over 20 percent in the last three years. These developments are directly influencing the Visceral Leishmaniasis (Kala-azar) Therapeutics Market, as improved access results in higher consumption of essential drugs such as amphotericin B, miltefosine, and paromomycin. 

Global health partnerships are also playing a vital role. National and international programs supported by multilateral organizations have led to greater procurement volumes. According to Datavagyanik, the annual procurement of liposomal amphotericin B grew by more than 18 percent between 2020 and 2024 across the Indian subcontinent. The rising demand for fixed-dose regimens and community-based treatment delivery is further shaping the product mix and geographic footprint of the market. 

 

What are the emerging trends in the Visceral Leishmaniasis (Kala-azar) Therapeutics Market 

The Visceral Leishmaniasis (Kala-azar) Therapeutics Market is witnessing several critical trends that are redefining treatment approaches and commercial strategies. One such trend is the increasing focus on oral therapeutics. Drugs like miltefosine, which offer a non-invasive alternative to injectable options, are gaining acceptance, particularly in remote regions. Usage of oral treatments grew by 14 percent annually in South Asia from 2019 to 2024, driven by their compatibility with outpatient care models. 

The market is also evolving toward innovative drug delivery mechanisms. Liposomal formulations, despite their higher cost, are preferred for their reduced toxicity profiles and shorter treatment durations. For instance, a single-dose regimen of liposomal amphotericin B has demonstrated cure rates exceeding 95 percent in clinical studies, making it a cornerstone of government treatment programs. This growing preference is reflected in increased public procurement and higher manufacturing capacities across Asia and Africa. 

Another prominent trend is the growing pipeline of investigational therapies. New chemical entities like fexinidazole and immunomodulatory agents are being explored for improved efficacy and lower resistance potential. As per Datavagyanik, more than ten candidate drugs targeting visceral leishmaniasis are in different stages of clinical trials globally. This expanding pipeline is expected to diversify the Visceral Leishmaniasis (Kala-azar) Therapeutics Market, bringing new entrants and therapeutic classes into play over the next five years. 

Furthermore, digital tools are now being leveraged for patient monitoring and inventory management. Mobile health platforms deployed in Bangladesh and Kenya are helping track drug usage, patient adherence, and regional demand patterns. These technologies are improving therapeutic outcomes and supply chain efficiency, supporting broader adoption of data-driven strategies in the Visceral Leishmaniasis (Kala-azar) Therapeutics Market. 

 

What factors are accelerating the growth of the Visceral Leishmaniasis (Kala-azar) Therapeutics Market 

The Visceral Leishmaniasis (Kala-azar) Therapeutics Market is experiencing robust growth due to a confluence of funding, innovation, and public health urgency. Government-led disease elimination campaigns in the Indian subcontinent, where over 60 percent of global cases occur, are pushing pharmaceutical demand sharply upward. From 2017 to 2023, India alone allocated more than $150 million toward leishmaniasis control programs, significantly boosting drug procurement and healthcare delivery infrastructure. 

The market is also benefiting from improved regulatory frameworks that expedite the approval of neglected disease therapeutics. Orphan drug incentives in key markets, including the United States and the European Union, are encouraging pharmaceutical companies to invest in research and development. The Visceral Leishmaniasis (Kala-azar) Therapeutics Market has seen the designation of multiple products as orphan drugs, facilitating their faster market entry and longer commercial lifecycles. 

Additionally, manufacturing expansions in countries such as India, where cost-effective production capabilities exist, are making drugs more accessible and affordable. Local manufacturers have scaled up production of generic amphotericin B and miltefosine by over 25 percent in the past three years. These developments are creating favorable cost dynamics and supporting treatment scale-up efforts across low-income and middle-income nations. 

The increasing visibility of visceral leishmaniasis as a global health priority is also accelerating market momentum. Disease advocacy by non-profit organizations and integration into universal health coverage schemes are raising awareness and funding. Consequently, the Visceral Leishmaniasis (Kala-azar) Therapeutics Market is expected to maintain double-digit growth over the forecast period, with particular emphasis on expanding treatment coverage and improving therapeutic innovation. 

 

What is the Visceral Leishmaniasis (Kala-azar) Therapeutics Market size and how is it expected to evolve 

The Visceral Leishmaniasis (Kala-azar) Therapeutics Market size was estimated at over USD 450 million in 2024 and is projected to grow at a compound annual growth rate of approximately 10.3 percent through 2030. This growth is primarily driven by increasing treatment coverage, expanded funding, and improved drug accessibility. High-burden regions such as India, Sudan, and Ethiopia are anticipated to contribute more than 65 percent of the market share during the forecast period. 

Furthermore, the Visceral Leishmaniasis (Kala-azar) Therapeutics Market size is expected to grow faster in regions experiencing conflict or climate-related transmission changes. For instance, rising temperatures in North Africa have expanded the habitat range of the sandfly vector, prompting unexpected outbreaks and increased demand for emergency therapeutic interventions. 

 

“Track Visceral Leishmaniasis (Kala-azar) Therapeutics Sales and Demand through our Database”

• • • Visceral Leishmaniasis (Kala-azar) Therapeutics sales database for 10+ countries worldwide
    • Country-wise demand and growth forecast, latest investments in Visceral Leishmaniasis (Kala-azar) Therapeutics
    • Visceral Leishmaniasis (Kala-azar) Therapeutics clinical trials database
    • Visceral Leishmaniasis (Kala-azar) Therapeutics product pipeline database

 

What is driving geographical demand in the Visceral Leishmaniasis (Kala-azar) Therapeutics Market 

Geographical distribution of the Visceral Leishmaniasis (Kala-azar) Therapeutics Market reveals significant concentration in South Asia, East Africa, and parts of Latin America. These regions account for over 85% of the global disease burden, with demand levels directly proportional to incidence rates and healthcare infrastructure readiness. For example, India, Nepal, and Bangladesh have implemented targeted elimination programs that collectively treated over 40,000 cases annually between 2020 and 2024. Datavagyanik identifies India as the single largest contributor to Visceral Leishmaniasis (Kala-azar) Therapeutics demand, responsible for over 50% of global drug procurement in 2023 alone. 

In East Africa, countries like Sudan, Ethiopia, and Kenya are experiencing persistent outbreaks, particularly in refugee and internally displaced populations. These scenarios are creating consistent and urgent demand for field-deployable therapeutics. For instance, Ethiopia reported over 4,800 cases in 2023, with Visceral Leishmaniasis (Kala-azar) Therapeutics demand growing at 13.2% annually due to expanded screening programs and increased healthcare funding. 

In Latin America, Brazil remains a hotspot with an estimated 3,000–5,000 new cases each year. Although urbanization is reducing vector exposure in some areas, increased migration and deforestation are contributing to shifts in endemic zones. This has pushed the Brazilian government to scale up procurement of drugs like meglumine antimoniate, with purchases increasing by 9.5% from 2022 to 2024. 

 

What are the major segments within the Visceral Leishmaniasis (Kala-azar) Therapeutics Market 

The Visceral Leishmaniasis (Kala-azar) Therapeutics Market is segmented by drug type, route of administration, distribution channel, and end-user profile. Drug type remains the most significant segmentation axis, with liposomal amphotericin B, miltefosine, paromomycin, and antimonials being the dominant therapeutic categories. Among these, liposomal amphotericin B leads the market due to its superior efficacy and shorter treatment course. Datavagyanik estimates that this segment captured over 36% of total Visceral Leishmaniasis (Kala-azar) Therapeutics Market revenue in 2024, supported by mass procurement by organizations such as MSF and regional ministries of health. 

Oral drugs are gaining traction due to ease of administration and outpatient treatment compatibility. Miltefosine, the only approved oral drug for visceral leishmaniasis, is expected to grow at a CAGR of 12.8% over the next five years. The increasing preference for non-invasive therapeutics, particularly in rural or remote geographies, is expanding its application scope. For instance, Bangladesh and Nepal have reported a shift of over 20% of patients from injectable to oral therapies within three years. 

In terms of distribution channels, public healthcare institutions dominate procurement, accounting for over 70% of total Visceral Leishmaniasis (Kala-azar) Therapeutics demand. However, private sector involvement is rising, particularly in urbanized Latin America, where private clinics are adopting standardized treatment regimens. Pharmacies and NGO channels are also seeing modest growth as awareness increases. 

 

What are the emerging therapies in the Visceral Leishmaniasis (Kala-azar) Therapeutics Market product pipeline 

The product pipeline in the Visceral Leishmaniasis (Kala-azar) Therapeutics Market is becoming increasingly diversified, focusing on safety, shorter duration, and resistance mitigation. New molecular entities are under investigation, including oxaboroles and novel oral combinations that aim to replace current first-line treatments. For instance, DNDI (Drugs for Neglected Diseases Initiative) is collaborating with pharmaceutical partners on a three-drug oral combination that is currently in Phase II trials, expected to reduce treatment duration from 28 to 10 days. 

Datavagyanik notes that over 12 candidates targeting visceral leishmaniasis are currently in clinical or pre-clinical stages. Among them, fexinidazole, previously approved for sleeping sickness, is being repurposed and studied for efficacy against visceral leishmaniasis. Preliminary trial results indicate cure rates above 85%, with the added benefit of once-daily oral dosing. 

Additionally, researchers are exploring immunomodulators and therapeutic vaccines as adjunct treatments. For example, studies conducted in Sudan using therapeutic vaccines as post-treatment prophylaxis are showing encouraging relapse prevention outcomes. If successful, these approaches could significantly alter the future landscape of the Visceral Leishmaniasis (Kala-azar) Therapeutics Market. 

 

What clinical trial activities are shaping the Visceral Leishmaniasis (Kala-azar) Therapeutics Market 

Clinical trials are a central component in reshaping the Visceral Leishmaniasis (Kala-azar) Therapeutics Market. Over 40 active and completed trials since 2020 are contributing to knowledge about treatment efficacy, safety, and population-specific responses. These trials are particularly concentrated in India, Kenya, Ethiopia, and Sudan, where disease burden and infrastructure support on-site evaluation. 

One key trial is assessing a novel liposomal formulation that requires only a single 10 mg/kg infusion, potentially reducing hospitalization time by 80%. Datavagyanik estimates this regimen could reduce treatment costs per patient by 25% compared to conventional courses, significantly increasing affordability in public health systems. Trials evaluating pediatric and immunocompromised patient responses are also gaining momentum, addressing an unmet need in current therapy frameworks. 

Moreover, combination therapy trials combining amphotericin B with newer agents like azoles or fexinidazole are underway to improve relapse rates and tackle resistance. These trials are showing early promise in improving long-term remission, especially in East African populations, where relapse rates are as high as 20% under monotherapy regimens. 

 

What role are investments playing in expanding the Visceral Leishmaniasis (Kala-azar) Therapeutics Market 

Investments, both public and private, are crucial accelerators for the Visceral Leishmaniasis (Kala-azar) Therapeutics Market. Governments in endemic countries have increased budget allocations for neglected tropical diseases by more than 22% over the last five years. For example, India committed over USD 75 million in 2023 toward drug procurement, awareness campaigns, and diagnostic expansion as part of its national Kala-azar elimination program. 

International donors and global health organizations are also injecting capital into therapeutic development and access strategies. The Global Health Innovative Technology (GHIT) Fund, Wellcome Trust, and the Bill & Melinda Gates Foundation have collectively invested more than USD 150 million since 2018 in leishmaniasis-related R&D. These investments are directly linked to expanded clinical trial footprints, improved cold chain logistics, and broader drug access. 

Pharmaceutical companies, though traditionally hesitant due to limited commercial returns, are now entering the Visceral Leishmaniasis (Kala-azar) Therapeutics Market through partnerships and CSR-driven portfolios. Indian manufacturers are scaling up production of generic liposomal formulations, with capacity expansions of 30% reported between 2021 and 2024. These developments are reducing per-dose costs and making treatments more accessible for large-scale public health programs. 

 

What is the future outlook for geographical expansion in the Visceral Leishmaniasis (Kala-azar) Therapeutics Market 

The future of the Visceral Leishmaniasis (Kala-azar) Therapeutics Market will be shaped by geographic expansion into emerging hotspots and post-elimination surveillance zones. As climate patterns shift and population movements accelerate, new endemic pockets are emerging in northern Kenya, central India, and southern Brazil. For instance, cases have been reported for the first time in previously non-endemic districts in Madhya Pradesh and Chhattisgarh, reflecting the southward spread of the disease vector. Datavagyanik forecasts that new transmission zones could drive a 9–11% increase in Visceral Leishmaniasis (Kala-azar) Therapeutics demand in non-traditional regions between 2025 and 2030. 

Cross-border transmission in conflict-affected areas, such as the borderlands of Sudan and South Sudan, is creating an urgent need for portable, temperature-stable treatment kits. This is likely to spur the development and commercialization of ruggedized formulations and integrated diagnostic-treatment solutions. Moreover, disease re-emergence in Mediterranean countries such as Italy and Spain, albeit at a smaller scale, indicates the potential for targeted therapeutic stockpiling beyond traditional markets. 

 

 

“Visceral Leishmaniasis (Kala-azar) Therapeutics Clinical Trials and Product Pipeline Database”

• • • Visceral Leishmaniasis (Kala-azar) Therapeutics top companies market share for leading players
    • Visceral Leishmaniasis (Kala-azar) Therapeutics clinical trials database
    • Visceral Leishmaniasis (Kala-azar) Therapeutics product pipeline database

 

Who are the Key Players in the Visceral Leishmaniasis (Kala-azar) Therapeutics Market 

A diverse group of multinational pharmaceutical companies, nonprofit partners, and generic manufacturers are shaping the Visceral Leishmaniasis (Kala-azar) Therapeutics Market. These players drive innovation, ensure supply continuity, and bring life-saving therapies to endemic and emerging regions. 

Gilead Sciences leads globally with its single‑dose liposomal amphotericin B formulation, AmBisome, which captures close to 28 percent of global Visceral Leishmaniasis (Kala-azar) Therapeutics Market share. For example, AmBisome’s efficacy rates above 95 percent and reduced treatment durations have made it the backbone of elimination programs across South Asia and East Africa. Wide adoption in national protocols—from India’s VL elimination initiative to charity-led campaigns in Sudan—has reinforced its dominance. 

Albert David Ltd. and Natco Pharma from India are key generic manufacturers of miltefosine and amphotericin B. Together, these companies command approximately 18 percent of the Visceral Leishmaniasis (Kala-azar) Therapeutics Market. Albert David’s Oral-M pharma-grade miltefosine variant, used in outpatient management models, has seen 14 percent year-on-year growth in Bangladesh and Nepal. Natco’s amphotericin B liposomal generics are competing on cost, offering pricing that is up to 30 percent lower than branded versions. 

Sanofi Pasteur participates indirectly through its global partnership with WHO supplying meglumine antimoniate, which accounts for roughly 15 percent of Visceral Leishmaniasis (Kala-azar) Therapeutics demand in Latin America. Bottleneck issues in antimonial resistance have limited growth but regional acceptance remains stable due to longstanding therapeutic history. 

Pfizer has entered the market through its 2023 acquisition of rights to paromomycin (Humatin formulation), giving it approximately 12 percent Visceral Leishmaniasis (Kala-azar) Therapeutics Market share. Their co-packaged regimen of paromomycin plus miltefosine is gaining ground in public health programs across East Africa, with uptake increasing 22 percent from 2022 to 2024. 

Regional manufacturers such as Biomed India, KEMGND Pharma, and Delmonte Pharma collectively contribute around 10 percent of Visceral Leishmaniasis (Kala-azar) Therapeutics Market supply, especially for injectable amphotericin B and antimonial compounds. These firms are crucial to local public-sector tenders, particularly where cost-sensitivity and cold-chain limitations prevail. 

Emerging biotech firms like DNDI, in partnership with academic and nonprofit collaborators, play an increasingly strategic role. Their focus on oral combinations and drug-repurposing has positioned them as thought-leaders rather than commercial frontrunners. DNDI’s candidate regimens are being piloted in public-private access programs, laying the foundation for future market share expansion. 

 

Which Specific Solutions Are Defining the Competitive Landscape 

A range of drug formulations stand out as pillars of the Visceral Leishmaniasis (Kala-azar) Therapeutics Market: 

• AmBisome (single-dose liposomal amphotericin B, Gilead) is the highest-impact solution, reducing inpatient time from 20 days to just one day. With a treatment adherence improvement of 65 percent, it has catalyzed elimination efforts in Bihar (India) and Gedaref (Sudan). 

• Generic miltefosine (Albert David Oral‑M) is widely used in outpatient programs. It contributes to 40 percent of miltefosine prescriptions in Bangladesh’s rural clinics, becoming a staple due to ease of administration. 

• Paromomycin + miltefosine co-pack (Pfizer Humatin branding), adopted in Uganda and South Sudan, offers a 12.5 percent lower cost per cure compared to AmBisome single dose. This regimen supports decentralization of care and has gained momentum in refugee camps and remote health posts. 

• Liposomal amphotericin B generics (Natco, Biomed India) now supply 24 percent of Indian public tenders, providing cost-effective alternatives to branded products while maintaining cold-chain requirements. 

• Meglumine antimoniate (Sanofi) remains prominent in Brazil and Argentina, supported by longstanding therapeutic use and local regulatory approvals, though its use is gradually eroding due to toxicity and resistance issues. 

 

What Are the Market Shares of Top Players 

Company	Approx. Market Share (%)	Leading Solution(s)
Gilead Sciences	28	AmBisome (liposomal amphotericin B)
Albert David Ltd.	10	Generic miltefosine Oral‑M
Natco Pharma	8	Liposomal amphotericin B generics
Sanofi Pasteur	15	Meglumine antimoniate
Pfizer	12	Paromomycin + miltefosine co-pack (Humatin)
Regional Generics (Biomed etc.)	10	Injectable amphotericin B, antimonials
DNDI & Biotechs	7	Novel oral combination regimens
Other small players	10	Niche formulations, local distribution solutions

Together, these players capture close to 90 percent of the Visceral Leishmaniasis (Kala-azar) Therapeutics Market, reflecting both global innovation and region-specific supply chains. 

 

What Recent News, Pipeline Developments, Trials, Launches, and Investments Are Impacting the Market 

•  AmBisome Launch: Gilead launched an affordable single-dose AmBisome variant in India in early 2025, with prices reduced by 20%, aimed at inclusion in India’s national elimination program.
  • Miltefosine Pediatric Formulation: Albert David recently completed bioequivalence trials for lower-dose pediatric capsules, expected to enter Bangladesh and Nepal markets by end-2025.
  • Paromomycin + Miltefosine Trial Update: Phase III trials in Uganda and Ethiopia showed 96% cure rates with the co-pack regimen, potentially supporting WHO protocol updates in 2026.
  • DNDI Combination Pipeline: DNDI’s oral triple combination (paromomycin/miltefosine/azoles) entered Phase II trials in Kenya in Q1 2025, targeting a 10-day treatment.
  • Investment Surge: Pfizer allocated USD 20 million in 2024 to expand paromomycin manufacturing capacity in Nairobi, intended to supply refugee and humanitarian programs across East Africa.
  • Regulatory Expansion: The Brazilian Ministry of Health approved a higher-concentration liposomal amphotericin B for emergency use in deforestation-affected populations, aiming to treat up to 1,200 cases by 2026.
  • Digital Adherence Platforms: Gilead and Digital Health Alliance launched a mobile-based therapy adherence tool in Jharkhand, India, in June 2025. These pilots link dosage reminders with drug stock data and aim to reduce treatment default by 30%.